(Q44659418)

5 December 2017

title

Advanced breast cancer updates on anastrozole versus tamoxifen (English)

1 reference

5 December 2017

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00374-1

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00374-1

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00374-1

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00374-1

3 April 2024

author name string

Arimidex Study Group

series ordinal

2

1 reference

5 December 2017

J. M. Nabholtz

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623528

3 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14623528

3 April 2024

publication date

1 September 2003

1 reference

full work available at URL

5 December 2017

https://api.elsevier.com/content/article/PII:S0960076003003741?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00374-1

https://api.elsevier.com/content/article/PII:S0960076003003741?httpAccept=text/plain

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00374-1

The Journal of Steroid Biochemistry and Molecular Biology

3 April 2024

published in

1 reference

5 December 2017

volume

86

1 reference

5 December 2017

issue

3-5

1 reference

5 December 2017

page(s)

321-325

1 reference

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900374-1

7 January 2021

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900374-1

7 January 2021

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900374-1

7 January 2021

Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900374-1

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900374-1

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900374-1

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900374-1

7 January 2021

Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer

series ordinal

4

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00374-1

3 April 2024

Identifiers

1 reference

5 December 2017

1 reference